Kaleido Bio Has Positive Interim Results with Mild-to-Moderate COVID-19

 Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities

Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021

https://www.globenewswire.com/news-release/2021/01/14/2158541/0/en/Kaleido-Biosciences-Announces-Positive-Interim-Results-of-Controlled-Study-of-KB109-in-Patients-with-Mild-to-Moderate-COVID-19.html